BROLUCIZUMAB
Total Payments
$4.7M
Transactions
590
Doctors
177
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $4.7M | 590 | 177 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.2M | 246 | 90.7% |
| Consulting Fee | $365,840 | 51 | 7.8% |
| Grant | $47,384 | 4 | 1.0% |
| Food and Beverage | $13,108 | 230 | 0.3% |
| Travel and Lodging | $7,835 | 59 | 0.2% |
Payments by Type
Research
$4.2M
246 transactions
General
$434,166
344 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 24-WEEK DOUBLE MASKED MULTICENTER TWO ARM EXTENSION STUDY TO COLLECT SAFETY AND EFFICACY DATA ON BROLUCIZUMAB 6 MG DRUG PRODUCT INTENDED FOR COMMERCIALIZATION IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION WHO HAVE COMPLETED THE CRTH258A2301 STUDY | Novartis Pharmaceuticals Corporation | $1.9M | 0 |
| A TWO YEAR RANDOMIZED DOUBLE MASKED MULTICENTER THREE ARM STUDY COMPARING THE SAFETY AND EFFICACY OF RTH258 VERSUS AFLIBERCEPT IN SUBJECTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATIONGE RELATED MACULAR DEGENERATION | Novartis Pharmaceuticals Corporation | $1.5M | 0 |
| A TWO YEAR, RANDOMIZED, DOUBLE MASKED, MULTICENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA | Novartis Pharmaceuticals Corporation | $743,052 | 0 |
| A TWO YEAR RANDOMIZED DOUBLE MASKED MULTICENTER THREE ARM STUDY COMPARING THE SAFETY AND EFFICACY OF RTH258 VERSUS AFLIBERCEPT IN SUBJECTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATIONGE RELATED MACULAR DEGENERATION | NOVARTIS PHARMACEUTICALS CORPORATION | $57,285 | 1 |
| A MULTICENTER RANDOMIZED DOUBLE MASKED PHASE 3A STUDY TO ASSESS SAFETY AND EFFICACY OF BROLUCIZUMAB 6 MG Q4 WEEKS COMPARED TO AFLIBERCEPT 2 MG Q4 WEEKS IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION NAMD WITH PERSISTENT RETINAL FLUID | Novartis Pharmaceuticals Corporation | $47,809 | 0 |
| A 24-WEEK DOUBLE MASKED MULTICENTER TWO ARM EXTENSION STUDY TO COLLECT SAFETY AND EFFICACY DATA ON BROLUCIZUMAB 6 MG DRUG PRODUCT INTENDED FOR COMMERCIALIZATION IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION WHO HAVE COMPLETED THE CRTH258A2301 STUDY | NOVARTIS PHARMACEUTICALS CORPORATION | $11,672 | 1 |
Top Doctors Receiving Payments for BROLUCIZUMAB
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Stephen Pakola | — | Elmsford, NY | $4.4M | 246 |
| , MD | Ophthalmology | Stanford, CA | $47,455 | 5 |
| , MD | Ophthalmology | Cleveland, OH | $30,769 | 13 |
| , MD | Ophthalmology | Pasadena, CA | $24,029 | 13 |
| , M.D | Ophthalmology | Reno, NV | $19,107 | 22 |
| , MD, PHD | Retina Specialist | Houston, TX | $16,406 | 11 |
| , M.D | Ophthalmology | Houston, TX | $15,356 | 6 |
| Philip Falcone | — | New Haven, CT | $14,595 | 2 |
| , M.D | Ophthalmology | Boston, MA | $14,491 | 9 |
| , MD | Ophthalmology | Orange, CA | $11,166 | 6 |
| Pravin Dugel | Ophthalmology | Phoenix, AZ | $9,993 | 9 |
| Jeffrey Heier | Ophthalmology | Boston, MA | $9,719 | 3 |
| , MD | Ophthalmology | Dallas, TX | $9,718 | 7 |
| , M.D | Retina Specialist | St Petersburg, FL | $9,179 | 7 |
| , MD | Ophthalmology | Cleveland, OH | $8,637 | 4 |
| , M.D | Ophthalmology | Tampa, FL | $8,521 | 6 |
| , M.D | Ophthalmology | Boulder, CO | $8,489 | 6 |
| , MD | Ophthalmology | Los Angeles, CA | $8,252 | 7 |
| , MD | Retina Specialist | Harvey, IL | $7,397 | 4 |
| , M.D | Ophthalmology | Cleveland, OH | $7,081 | 6 |
| , M.D | Ophthalmology | Rochester, MN | $6,671 | 7 |
| , MD | Retina Specialist | Minneapolis, MN | $6,650 | 1 |
| , M.D | Ophthalmology | Lutherville, MD | $6,077 | 6 |
| , MD | Ophthalmology | Plymouth Meeting, PA | $5,651 | 6 |
| , MD | Specialist | New York, NY | $3,430 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.7M
- Total Doctors 177
- Transactions 590
About BROLUCIZUMAB
BROLUCIZUMAB is a drug associated with $4.7M in payments to 177 healthcare providers, recorded across 590 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2018. In 2018, $4.7M was paid across 590 transactions to 177 doctors.
The most common payment nature for BROLUCIZUMAB is "Unspecified" ($4.2M, 90.7% of total).
BROLUCIZUMAB is associated with 6 research studies, including "A 24-WEEK DOUBLE MASKED MULTICENTER TWO ARM EXTENSION STUDY TO COLLECT SAFETY AND EFFICACY DATA ON BROLUCIZUMAB 6 MG DRUG PRODUCT INTENDED FOR COMMERCIALIZATION IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION WHO HAVE COMPLETED THE CRTH258A2301 STUDY" ($1.9M).